Navigating the New EU Medical Devices Regulation: Retrospective Post-Market Follow-Up of Hyaluronic Acid Injections for Knee Osteoarthritis
- PMID: 38529260
- PMCID: PMC10962269
- DOI: 10.2147/OARRR.S446572
Navigating the New EU Medical Devices Regulation: Retrospective Post-Market Follow-Up of Hyaluronic Acid Injections for Knee Osteoarthritis
Abstract
Purpose: The entry into force of the new Medical Device Regulation (EU) 2017/745 highlights the need for post-market clinical follow-up to ensure the safety and efficacy throughout the life cycle of medical devices. This study evaluates the efficacy and safety of a single intra-articular hyaluronic acid injection in knee osteoarthritis in real-world conditions, over a six-month period, aligning with the summary of safety and clinical performance (SSCP) required by the new regulation.
Patients and methods: Patients over 18 years of age with knee osteoarthritis, treated with a single injection of HA (Adant® One, Meiji Pharma Spain, Spain) at a 3rd level hospital. Patients were treated and followed between January 1, 2020 and June 30, 2022. Demographic, clinical, and treatment-related data were collected, and efficacy regarding pain relief and/or function improvement was assessed using a Likert-type scale. Data were pseudo-anonymized and the comparison was performed using Fisher' or Mann Whitney' test. The study was approved by the Ethics Review Board of the Hospital Puerta de Hierro (Madrid, Spain).
Results: We followed 20 patients with knee osteoarthritis, with a mean age of 61 years, 80% women, and with a high burden of comorbidities (90%). A total of 60% of patients presented Kellgren-Lawrence grade III-IV. Four patients (20%) returned before 6 months due to lack of efficacy. Of the other patients, 65% showed a clinical response that lasted more than 12 months in 38.5% of cases. Time until medical appointment and taking concomitant medication for knee osteoarthritis were associated with better clinical response (p < 0.05).
Conclusion: The administration of a Adant® One single intra-articular hyaluronic acid injection in knee osteoarthritis is effective, safe, and maintains the improvement over a six-month period. Our findings also emphasize the need of using standardized tools for accurate efficacy assessment and optimal patient care.
Keywords: real clinical practice; rehabilitation; rheumatology; traumatology.
© 2024 Alcina Navarro et al.
Conflict of interest statement
MP. Coronel and M. Gimeno del Sol are employees of Meiji Pharma Spain. The other authors report no conflicts of interest in this work.
Similar articles
-
Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.Ont Health Technol Assess Ser. 2005;5(10):1-66. Epub 2005 Jun 1. Ont Health Technol Assess Ser. 2005. PMID: 23074461 Free PMC article.
-
Efficacy and Safety of One Shot of Hyaluronic Acid in Hip Osteoarthritis: Postmarketing Clinical Follow-Up for Real-World Evidence.Open Access Rheumatol. 2024 Dec 10;16:157-163. doi: 10.2147/OARRR.S485295. eCollection 2024. Open Access Rheumatol. 2024. PMID: 39677564 Free PMC article.
-
One-year follow-up showing effects of single intra-articular injection of hyaluronic acid (1,500-2,000 kDa) in symptomatic knee osteoarthritis.J Biol Regul Homeost Agents. 2018 Nov-Dec;32(6):1433-1441. J Biol Regul Homeost Agents. 2018. PMID: 30574747
-
Intra-articular hyaluronic acid in knee osteoarthritis: clinical data for a product family (ARTHRUM), with comparative meta-analyses.Curr Ther Res Clin Exp. 2021 Sep 20;95:100637. doi: 10.1016/j.curtheres.2021.100637. eCollection 2021. Curr Ther Res Clin Exp. 2021. PMID: 34712370 Free PMC article. Review.
-
Platelet-Rich Plasma Combined With Hyaluronic Acid Improves Pain and Function Compared With Hyaluronic Acid Alone in Knee Osteoarthritis: A Systematic Review and Meta-analysis.Arthroscopy. 2021 Apr;37(4):1277-1287.e1. doi: 10.1016/j.arthro.2020.11.052. Epub 2020 Dec 3. Arthroscopy. 2021. PMID: 33278533
Cited by
-
One shot of hyaluronic acid in advanced knee osteoarthritis: postmarketing clinical follow-up for real-world evidence in a pain unit.BMC Musculoskelet Disord. 2025 Jul 3;26(1):589. doi: 10.1186/s12891-025-08875-7. BMC Musculoskelet Disord. 2025. PMID: 40611078 Free PMC article.
References
LinkOut - more resources
Full Text Sources